Department of Radiology, Hyssensstift Kliniken-Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany.
Anticancer Res. 2011 Aug;31(8):2575-81.
To retrospectively evaluate the diagnostic value of high-frequency ultrasound for the detection of microcalcifications screening in BI-RADS 4a patients.
A total of 52 women (mean age 60.5±6.5 years) classified as BI-RADS 4a with microcalcifications, but without associated masses after X-ray mammography (XRM) underwent ultrasound (US) examination (B-mode, ApliPure™ , and MicroPure™ imaging). The results were assessed by two independent investigators and analyzed in relation to the B-classification. Written informed consent was obtained before enrolment.
The rate of US microcalcification detection was 98.1% (B-mode), 100% (ApliPure™) and 25% (MicroPure™), respectively. The microcalcification extent was significantly underestimated with all US modalities in comparison with XRM, but the difference was lower for ApliPure™ as compared to B-mode. ApliPure™ was also superior in terms of puncture feasibility, facilitating US-guided biopsy in 67.3% as compared to 48.1% (B-mode) and 15.4% (MicroPure™).
In BI-RADS 4a patients, both high-frequency B-mode US and ApliPure™ imaging are highly sensitive for the detection of microcalcifications, whereas MicroPure™ ultrasound imaging is unsuitable. ApliPure™ imaging allowed US guided biopsy for 67.3% of lesions, providing a convenient and economical alternative to stereotactically guided biopsy.
回顾性评估高频超声在 BI-RADS 4a 患者微钙化筛查中的诊断价值。
共 52 名女性（平均年龄 60.5±6.5 岁），经 X 线乳房摄影术（XRM）检查后分类为 BI-RADS 4a 并伴有微钙化，但无相关肿块，均行超声（B 型、ApliPure™和 MicroPure™成像）检查。由两名独立的研究者评估结果，并与 B 分类相关进行分析。在入组前获得书面知情同意。
US 微钙化的检出率分别为 98.1%（B 型）、100%（ApliPure™）和 25%（MicroPure™）。与 XRM 相比，所有 US 模式下微钙化的程度均明显低估，但 ApliPure™ 与 B 型相比差异较低。ApliPure™在穿刺可行性方面也具有优势，可在 67.3%的情况下进行 US 引导活检，而 B 型为 48.1%，MicroPure™为 15.4%。
在 BI-RADS 4a 患者中，高频 B 型超声和 ApliPure™成像对微钙化的检测均具有高度敏感性，而 MicroPure™超声成像则不适用。ApliPure™成像允许对 67.3%的病变进行 US 引导活检，为立体定向引导活检提供了一种方便且经济的替代方法。
